Cervical cancer screening could be less frequent, start later

October 17, 2016, Harvard T.H. Chan School of Public Health
High grade dysplasia (carcinoma in situ) in the uterine cervix. The abnormal epithelium is extending into a mucus gland to the left of centre. This disease can progress to invasive cancer (squamous cell carcinoma) of the cervix. Credit: Haymanj/public domain

Women may only need cervical cancer screening every 5-10 years—instead of every three years, as currently recommended—and may be able to start the screenings later in life, according to a new study from Harvard T.H. Chan School of Public Health.

The researchers found that less-intensive screening is needed among women who have been vaccinated against human papillomavirus (HPV), which causes almost all cases of cervical cancer, because the risk of these women developing cervical cancer is quite low.

The study will appear October 17, 2016, in the Journal of the National Cancer Institute (JNCI).

"This analysis enabled us to examine what would happen if we shifted from the current way we screen for cervical cancer—essentially, recommending the same type of screening for all women—to screening that takes into account whether women have been vaccinated against HPV and therefore face a substantially lower risk of cervical cancer," said Jane Kim, professor of health decision science at Harvard Chan School. "We found that continuing intensive screening among HPV-vaccinated women yields excessive costs and harms with little to no health benefit."

Since 2012, major guideline-making organizations have recommended that all women in the U.S. be screened for cervical cancer every three years beginning at age 21 with a Pap test (which checks for abnormal cells in the cervix), with the option of switching to a combination of Pap test and HPV testing (known as "cotesting") every five years beginning at age 30. However, current U.S. guidelines don't differentiate screening recommendations based on a woman's HPV vaccination status.

The Harvard Chan researchers developed a disease simulation model to estimate the risks and benefits of various screening protocols. Their model projected the health and economic effects of three different types of HPV vaccines that are currently approved for use, two of which have been available since 2006. The goal was to pinpoint screening strategies that would provide the biggest in the most cost-effective way.

According to the model, women with the lowest risk of cervical cancer—those vaccinated with the new "nonavalent" HPV vaccine (HPV-9), which targets seven types of HPV that cause nearly 90% of all cervical cancers—would only need screening four times in their life, every 10 years, starting at age 30 or 35. Women vaccinated with earlier versions of the HPV vaccine—the bivalent and quadrivalent vaccines (HPV-2 and HPV-4), which target two HPV types that cause roughly 70% of cervical cancers—would need screening every five years starting at age 25 or 30.

The researchers also found that screening with HPV testing alone would provide similar health benefits and value as a Pap test or cotesting, because the HPV test is highly sensitive and can more efficiently identify women who are likely to develop .

One limitation of the study is that it modeled scenarios in which women are fully vaccinated in pre-adolescence (as recommended) and fully compliant with screening protocols. The researchers noted that future studies should take into account actual vaccination uptake rates in the population and data on screening compliance in vaccinated women as these data become available over time.

Explore further: More than two-thirds of cervical cancer deaths prevented by screening

More information: "Optimal cervical cancer screening in women vaccinated against human papillomavirus," Jane J. Kim, Emily A. Burger, Stephen Sy, Nicole G. Campos, Journal of the National Cancer Institute, October 17, 2016, DOI: 10.1093/jnci/djw216

Related Stories

More than two-thirds of cervical cancer deaths prevented by screening

September 19, 2016
Cervical screening prevents 70 per cent of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83 per cent, according to research led by Queen Mary University of London (QMUL).

HPV vaccine reduced cervical abnormalities in young women

July 4, 2016
Young women who received the human papillomavirus (HPV) vaccine through a school-based program had fewer cervical cell anomalies when screened for cervical cancer, found a new study in CMAJ (Canadian Medical Association Journal).

Low incidence of cervical cancer, CIN3+ for HPV-negative women

October 7, 2016
(HealthDay)—Human papillomavirus (HPV)-negative women have low long-term incidence of cervical cancer and cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+), which supports an extension of the cervical screening ...

ACOG: New recommendations for cervical cancer screening

December 23, 2015
(HealthDay)—In a practice bulletin published in the January issue of Obstetrics & Gynecology, new recommendations are presented for cervical cancer screening and prevention.

What's the best test for cervical cancer? Pap, HPV or both?

June 9, 2014
Should U.S. women be screened for cervical cancer with Pap tests, HPV tests or both? According to researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) while the merits of screening ...

Routine screenings prevent cervical cancer in elderly women

July 7, 2016
A new study from the University of Illinois confirms a link between routine Pap smear screenings and a lower risk of developing cervical cancer in women over age 65. However, most American health guidelines discourage women ...

Recommended for you

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment

June 15, 2018
Two research teams converge on epigenetic switches that feed treatment-resistant metastatic prostate tumors. This research highlights the value of exploring gene regulation and large-scale structural changes in the cancer ...

Researchers peer inside cells to spy on cancer's on-off switch

June 15, 2018
Forty years after researchers first discovered it in fruit flies, a once-obscure cluster of proteins called PRC2 has become a key target for new cancer-fighting drugs, due to its tendency—when mutated—to bind to and silence ...

PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform

June 15, 2018
The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina (MUSC) investigators in an article ...

Gene testing could identify men with prostate cancer who may benefit from immunotherapy

June 14, 2018
Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.

Without 'yoga and chardonnay' leukemia stem cells are stressed to death

June 14, 2018
Change is stressful. The change that a healthy blood stem cell undergoes to become a leukemia stem cell (LSC) is no exception—think of healthy blood stem cells as young professionals and the transformation into an LSC as ...

Statins found to enhance efficacy of chemotherapy drug in blood cancers

June 14, 2018
A team of researchers with members affiliated with several institutions in the U.S. has found that some statins could enhance the efficacy of a chemotherapy drug used to fight blood cancers in mouse models. In their paper ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.